#AS­CO17: Epizyme will hunt a quick OK for tazeme­to­stat, de­spite dis­ap­point­ing an­a­lysts with new da­ta

As the dust be­gan to set­tle from the AS­CO ab­stract drop last night, sev­er­al an­a­lysts weighed in not­ing their cau­tious lack of op­ti­mism for Epizyme’s lat­est look at the da­ta for tazeme­to­stat, its EZH2 in­hibitor now in Phase II for ep­ithe­lioid sar­co­ma.

RBC’s Matthew Eck­ler not­ed the lat­est da­ta were “be­low our ex­pec­ta­tions.”

For Ge­of­frey Porges at Leerink: “These re­sults squeaked over the tri­al’s hur­dle for pro­ceed­ing to co­hort ex­pan­sion and the 13% ORR is be­low our men­tal thresh­old of a 20-30% re­sponse rate.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER